Posts

Roche buys Point-of-Care Technology Platform from LumiraDx

Swiss pharmaceutical company Roche announced its agreement to acquire LumiraDx’s...

EMA validates BMS’s repotrectinib application to treat ...

The EMA has validated the marketing authorisation application of Bristol Myers S...

MediLink and Roche partner on cancer drug development

MediLink Therapeutics has signed a global partnership and licence deal with Roch...

PDS-01ADC by PDS Biotechnology for Colorectal Cancer: L...

PDS-01ADC is under clinical development by PDS Biotechnology and currently in Ph...

Boehringer reinforces interest in NASH with new $2bn de...

This collaboration comes six years after the German company Boehringer signed tw...

Novartis allies with Voyager to develop gene therapies ...

Novartis will pay Voyager $100m upfront and up to $1.2bn in milestone-based paym...

Signal: FTC granted injunction to pause IQVIA’s acquisi...

A US court has granted the FTC's request to halt the acquisition due to concerns...

Expert analysis: the latest in HIV research and clinica...

A new report from Novotech delves into the multifaceted landscape of HIV, focusi...

Diakonos’ brain tumour vaccine wins FDA’s orphan drug d...

The immuno-oncology company has also completed enrolment in a Phase I trial inve...

UK MHRA introduces new procedure for medicine approvals

The UK MHRA has introduced the International Recognition procedure (IRP), a new ...

Oragenics acquires neurological assets from Odyssey Health

Oragenics has concluded the announced acquisition of assets focusing on neurolog...

STAT+: Pharmacies fear New Year’s financial squeeze fro...

Under a new policy, there will be a period when pharmacies are being billed PBM ...

STAT+: 2024 could be a turning point for the regulation...

In health care, predictive AI models may have to explain how their systems were ...

Opinion: Today’s at-home microbiome testing industry is...

A gastroenterologist explains why patients who are investing in at-home microbio...

STAT+: Consumer health advocate Sid Wolfe was a thorn i...

Passionate and meticulous, Sid Wolfe, who died Sunday, was the consummate public...

STAT+: A single drug and multiple study failures leave ...

It took Anavex Life Sciences seven months to finally acknowledge the failure of ...